FDA approves Celltrion’s biosimilar of J&J’s Stelara
by
Contributor since / Followers
Contributor since / Followers
14 hours ago
- The FDA has approved Steqeyma, a biosimilar of Johnson & Johnson’s (NYSE:JNJ) blockbuster drug Stelara.
- Steqeyma, which was developed by South Korea’s Celltrion, was approved for the treatment of adults with Crohn’s disease and ulcerative colitis and for adults and children aged